First patient worldwide dosed in a Phase 2 angiokeratoma trial

Angiokeratoma affects more than 50,000 people in the U.S. and has no FDA-approved therapy today. One of our sites recently enrolled and dosed the first patient worldwide in a Phase 2 angiokeratoma trial.

For a condition with no approved treatment, every step in a trial like this matters. The milestone reflects the speed and readiness our embedded model brings to rare-disease research, and we are grateful to the patient who took part, along with our team and partners.

All news